The U.S. Food and Drug Administration announced on October 5, 2026 that it is requesting public input on how early-phase clinical trials of ibogaine drug products should be designed, according to the official release. The request for information comes as the agency works to advance a presidential directive on psychedelic medicine while addressing what it describes as serious safety concerns tied to the compound.

Key takeaways

  • The FDA issued a request for information (RFI) on October 5, 2026, seeking public input on designing early-phase clinical trials for ibogaine drug products.
  • The agency is asking about dose selection, with a proposed starting dose not exceeding 10 mg/kg, as well as safety monitoring, eligibility criteria and stopping rules.
  • The public comment period runs 45 days after Federal Register publication and closes Friday, November 20, 2026, under Docket No. FDA-2026-N-10429.
  • HHS is prioritizing two initial patient populations for federally supported ibogaine research: adults with opioid use disorder and adults with post-traumatic stress disorder.

What the FDA Is Asking For

The request for information, formally opened under Docket No. FDA-2026-N-10429, seeks comments, data and information on specific protocol elements relevant to ibogaine drug development. According to the FDA, these elements include dose selection and escalation, care setting, safety monitoring, eligibility criteria, stopping rules and safety oversight.

The agency said it is seeking comments, data and information in four primary areas.

Michael Davis, M.D., Ph.D., Director of the FDA Center for Drug Evaluation and Research, said in the release that "Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches." He added, "With ibogaine, there are important scientific questions as well as serious safety concerns. We are seeking high-quality data and input that can help inform clinical research while putting patient safety first."

The Numbers and Timeline at a Glance

The release lays out a clear set of figures and dates governing the comment process and the proposed dosing parameter under consideration.

MeasureLatest figurePrevious or comparison figureChange
Comment period length45 days following Federal Register publicationNot statedNot stated
Comment deadlineFriday, November 20, 2026Not statedNot stated
Proposed starting dose ceilingNot exceeding 10 mg/kgNot statedNot stated
Docket numberFDA-2026-N-10429Not statedNot stated

Stakeholders have been encouraged to submit comments electronically at regulations.gov by searching for the docket number, or to send written submissions to the FDA's Dockets Management Staff at 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. The FDA stated plainly that late comments will not be considered after the November 20 deadline.

How This Fits Into Broader Federal Action on Psychedelics

The RFI marks what the FDA called its latest action to advance President Trump's April 2026 executive order on Accelerating Medical Treatments for Serious Mental Illness, which directed federal agencies to accelerate research into psychedelic medicine. The agency said it has been working across the federal government to support the responsible development of ibogaine drug products through careful, evidence-based processes.

In July 2026, the FDA issued finalized guidance for industry titled Psychedelic Drugs: Considerations for Clinical Investigations, providing general considerations for sponsors developing psychedelic drugs. The agency also noted it has allowed an early-phase clinical study of noribogaine hydrochloride, a derivative of ibogaine, to proceed under an Investigational New Drug application as a potential treatment for alcohol use disorder.

As part of what the FDA described as a whole-of-government approach, the Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), is funding a program to collect safety and efficacy data through early-phase clinical trials. The National Institute on Drug Abuse (NIDA) is separately funding research on ibogaine for the potential treatment of opioid use disorder. Based on available data and the seriousness of the conditions, HHS said it is prioritizing two initial populations for federally supported research: adults with opioid use disorder and adults with post-traumatic stress disorder.

Why the FDA's Drug Review Process Matters Here

The FDA, an agency within the U.S. Department of Health and Human Services, is responsible for protecting public health by assuring the safety, effectiveness and security of human and veterinary drugs, as well as vaccines, biological products, medical devices, food, cosmetics and tobacco products. Before any new drug can be approved for marketing, sponsors must typically conduct phased clinical trials, starting with small early-phase studies focused on safety and dosing, moving toward larger trials that test effectiveness in specific patient populations.

Requests for information like this one allow the FDA to gather outside expertise, data and perspectives from researchers, patient advocates, clinicians and industry before finalizing its own internal thinking on how trials in a given area should be structured. This step is distinct from a formal guidance document or a drug approval decision; it is a preliminary information-gathering exercise feeding into future agency policy, similar in spirit to how the FDA has recently moved on other emerging treatment areas such as its approval of a first-of-its-kind treatment for chronic hepatitis B or its accelerated approval pathway used for certain rectal cancer patients.

Frequently asked questions

What is ibogaine and why is the FDA focused on it now?

The release identifies ibogaine as a psychedelic compound of scientific interest, with the agency citing both potential benefits and serious safety concerns, including risks of cardiac and neurologic adverse events. The FDA's current action is tied to a presidential executive order directing agencies to accelerate research into psychedelic medicine for serious mental illness.

Who can submit comments and how?

According to the FDA, stakeholders can submit comments electronically at regulations.gov by searching for Docket No. FDA-2026-N-10429, or send written and paper submissions to the FDA's Dockets Management Staff at the Rockville, Maryland address listed in the release. The comment window closes Friday, November 20, 2026, and the FDA stated late comments will not be considered.

Which patients would ibogaine research initially target?

HHS said it is prioritizing two initial populations for federally supported ibogaine research: adults with opioid use disorder and adults with post-traumatic stress disorder. This prioritization reflects funding decisions by ARPA-H and the National Institute on Drug Abuse described in the release, rather than an approved treatment indication.